Daniel Janney Overview

  • Investor Type
  • Angel
  • Investments
  • 1
  • Portfolio
  • 1
  • Exits
  • 1
Exits

Daniel Janney General Information

Description

Mr. Daniel Janney serves as Managing Director at Alta Partners. He serves as Board Member at Be Biopharma. He joined Alta immediately following the firm's founding in 1996, and was a co-founder of the Alta BioPharma effort. Dan focuses on investments in biopharmaceutical products and therapeutics. He has been directly involved in the funding and development of over 25 life sciences companies. Dan is, or has served on the board of directors of a number of companies, including Alba Therapeutics, Allakos, DiscoveRx, Esperion Therapeutics, Lithera, Prolacta Bioscience and ViroBay. In addition, he led Alta's investments in ChemGenex Pharmaceuticals, CoTherix, Definity Health, Dynavax, Endonetics, Ilex Oncology, InterMune, LJL Biosystems and Mako Surgical. He served as a Board Member at Evolve BioSystems and Sutro Biopharma. Prior to joining Alta, he was a senior investment banker at Montgomery Securities, focusing on life sciences companies. Dan is also a member of The President's Council of the Gladstone Institutes. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles. He also serves as Board Member of Novome Biotechnologies. He also serves as Board Member at Lassen Therapeutics. Dan Janney has been investing in life sciences companies for more than 20 years. Dan joined Alta Partners at its founding and is a Managing Director. His focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 32 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. Dan is currently on the board of directors of several public and private companies, including Esperion Therapeutics, Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve. In addition, he led Alta's investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (acquired by Cephalon), CoTherix (acquired by Actelion), DeUnity Health (acquired by United Health), Dynavax, Endonetics (acquired by Medtronic), Ilex Oncology (acquired by Millennium Pharmaceuticals), InterMune (acquired by Roche), LJL Biosystems (acquired by Molecular Devices), Mako Surgical (acquired by Stryker) and Triangle Pharmaceuticals (acquired by Gilead).

Contact Information

Primary Investor Type
Angel (individual)
Primary Office
  • 4 Embarcadero Center
  • Suite 2100
  • San Francisco, CA 94111
  • United States
+1 (415) 000-0000

Daniel Janney Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
0000000.000 08-Jul-2016 0000 00000 00.000 Entertainment Software Generating Revenue 000000 000000
To view Daniel Janney’s complete investments history, request access »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Daniel Janney Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Daniel Janney Team (1)

Name Title Deals Funds Boards Office
Daniel Janney Angel Investor 00 00 0 San Francisco, CA
To view Daniel Janney’s complete team members history, request access »